Nomination Committee Appointed for BioInvent International’s Annual General Meeting 2022
LUND, SWEDEN / ACCESSWIRE / November 25, 2021 / BioInvent International (STO:BINV)
Lund, Sweden - November 25, 2021 - The members of the Nomination Committee for BioInvent International AB:s (publ) ("BioInvent") Annual General Meeting in 2022 have now been appointed.
The following representatives of BioInvent International AB's shareholders will be members of the Nomination Committee for the Annual General Meeting 2022:
- Laura Feinleib, appointed by Redmile Group, LLC
- Erik Esveld, appointed by van Herk Investments B.V.
- Vincent Ossipow, appointed by Omega Funds, LP
- Leonard Kruimer, Chairman of the Board
The Nomination Committee shall prepare proposals for the Annual General Meeting in 2022 regarding Chairman of the General Meeting, Chairman of the Board and other Board members, board remuneration shared among the Chairman and other Board members, possible compensation for committee work, and election of auditors and auditor's fees.
The Annual General Meeting will be held on April 28, 2022 in Lund, Sweden.
Proposals to the Nomination Committee can be sent to Stefan Ericsson, by mail: BioInvent International AB (publ).), SE-223 70 Lund or telephone: +46 (0)46-46 286 85 50 in good time before March 10, 2022
For further information, please contact:
Senior Director Investor Relations
Tel: +46 46 286 85 50
BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com. Follow us on Twitter: @BioInvent.
SOURCE: BioInvent International
View source version on accesswire.com:
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
iZafe Group29.11.2021 08:52:06 CET | Press release
iZafe Group Q3 Interim Report, July-September 2021
Smart Eye25.11.2021 15:09:03 CET | Press release
Smart Eye completes the acquisition of iMotions
Bambuser AB25.11.2021 14:43:21 CET | Press release
BuzzFeed Taps Bambuser to Create Live Video Shopping Initiatives
STRAX25.11.2021 09:06:51 CET | Press release
Interim Report no. 3 for Financial Year 2021
Adverty AB25.11.2021 08:21:29 CET | Press release
Adverty Partners With Smart to Further Facilitate Access to Its Seamless in-Game Inventory
TECO 2030 ASA25.11.2021 07:01:35 CET | Press release
TECO 2030 is Leading a Project Group That Will Build A Hydrogen-Powered High-Speed Vessel For The Port of Narvik
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom